| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 08/15/2001 | CN1069534C Preparation method for medicine of reducing blood sugar using natural bitter gourd extract |
| 08/14/2001 | US6274740 Dissolving crystal form in solvent; drying |
| 08/14/2001 | US6274736 Chromatographic enantiomer separation of lactones |
| 08/14/2001 | US6274618 Administering (-)-cis-6-phenyl-5-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl)-5,6,7,8 -tetrahydronphthalen-2-ol to treat vaginal dryness, itching, or painful intercourse |
| 08/14/2001 | US6274605 Administering an insulin sensitivity enhancer with an angiotensin converting enzyme inhibitor to reduce side effects to a diabetic patient |
| 08/14/2001 | US6274594 Isoquinoline derivatives and their therapeutical use |
| 08/14/2001 | US6274582 Reduction of visceral fat |
| 08/14/2001 | US6274580 Aminoguanidine carboxylate lactams for the treatment of non-insulin-dependent diabetes mellitus |
| 08/14/2001 | US6274579 Pharmaceutically active morpholinol |
| 08/14/2001 | US6274577 Autoimmune diseases; antiinflammatory agents |
| 08/14/2001 | US6274556 Administering polypeptide derivative to treat inflammatory bowel disease and to prevent leukocyte infiltration into tissues |
| 08/14/2001 | US6274549 Administering genetically engineered human insulin with deletion or substitution |
| 08/14/2001 | US6274360 Conversion of compactin to pravastatin by Actinomadura |
| 08/14/2001 | US6274166 Transdermal delivery system |
| 08/14/2001 | US6274161 Compositions containing creatine in suspension |
| 08/14/2001 | CA2180464C Enteral formula with ribo-nucleotides |
| 08/14/2001 | CA2148380C 5-arylindole derivatives |
| 08/14/2001 | CA2083754C Stable vitamin and/or carotenoid products in powder form, and the preparation thereof |
| 08/14/2001 | CA2035179C Pharmaceutical compositions containing insoluble salts of bisphosphonic acids |
| 08/14/2001 | CA2014545C Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them |
| 08/14/2001 | CA1341284C Site-directed mutagenesis modified glycoprotein hormones and methods of use |
| 08/09/2001 | WO2001057267A1 Methods and materials relating to cub domain polypeptides and polynucleotides |
| 08/09/2001 | WO2001057261A1 Methods and materials relating to leucine-rich repeat protein-like (lrr protein-like) polypeptides and polynucleotides |
| 08/09/2001 | WO2001057233A2 Methods and materials relating to preadipocyte factor-1-like (pref-1-like) polypeptides and polynucleotides |
| 08/09/2001 | WO2001057085A2 G-protein coupled receptors |
| 08/09/2001 | WO2001057081A2 Narc-1, subtilase-like homologs |
| 08/09/2001 | WO2001057078A1 Process for producing dialytic amyloid fiber polymerization nuclei, method of screening remedies for dialytic amyloidosis and remedies for dialytic amyloidosis |
| 08/09/2001 | WO2001057036A1 Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes |
| 08/09/2001 | WO2001057026A1 Compounds having antitumor activity: process for their preparation and pharmaceutical compositions containing them |
| 08/09/2001 | WO2001057022A2 Pyrazole compositions useful as inhibitors of erk |
| 08/09/2001 | WO2001057008A1 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
| 08/09/2001 | WO2001057002A1 Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same |
| 08/09/2001 | WO2001056993A2 Pyrazole compositions useful as inhibitors of erk |
| 08/09/2001 | WO2001056983A2 Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate |
| 08/09/2001 | WO2001056981A1 Use of vitamin d-derivatives in the treatment of osteoporosis and related bone disorders, as well as novel vitamin d3-derivatives |
| 08/09/2001 | WO2001056959A1 A substance for the use in a dietary supplementation or for the preparation of a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome |
| 08/09/2001 | WO2001056596A1 Use of lysosomal acid lipase for treating atherosclerosis and related diseases |
| 08/09/2001 | WO2001056589A2 Physiologically active compositions of basidiomycotina and araliaceae extracts |
| 08/09/2001 | WO2001056567A1 2,4-diaminothiazole derivatives and their use as glycogen synthase kinase-3 (gsk-3) inhibitors |
| 08/09/2001 | WO2001056560A1 Substituted amino acids as neutral sphingomyelinase inhibitors |
| 08/09/2001 | WO2001056547A2 Preparation of aqueous clear solution dosage forms with bile acids |
| 08/09/2001 | WO2001056405A2 A method for maintaining or improving the synthesis of mucins |
| 08/09/2001 | WO2001056404A1 Low molecular weight polymannuronate |
| 08/09/2001 | WO2001056382A1 Novel diphenylethylene compounds |
| 08/09/2001 | WO2001032596A8 Phenoxy carboxylic acid compounds and compositions for delivering active agents |
| 08/09/2001 | WO2001016312A3 Nucleic acid based modulators of gene expression |
| 08/09/2001 | WO2001004318A3 Myxoma virus genes for immune modulation |
| 08/09/2001 | WO2000073324A9 Modulation of gene expression in gastrointestinal inflammation |
| 08/09/2001 | WO2000071506A3 Naphthalene ureas as glucose uptake enhancers |
| 08/09/2001 | WO2000070046A9 Secreted polypeptides and corresponding polynucleotides |
| 08/09/2001 | WO2000069257A3 Genetic modification of male germ cells for generation of transgenic species and genetic therapies |
| 08/09/2001 | WO2000066094A3 Use of compounds with a nitrogen-oxygen heterocycle as anti-infectious agents |
| 08/09/2001 | WO2000063351A3 Carbohydrate-modifying enzymes |
| 08/09/2001 | WO2000005224A3 Heterocyclic derivatives and their use as integrin inhibitor |
| 08/09/2001 | US20010012855 Administering to the mammal an effective amount of a venlafaxine derivative to treat obesity, panic disorder, post-traumatic stress disorder, attention deficit disorder, Gilles de la Tourette syndrome, bulimia nervosa, anxiety etc. |
| 08/09/2001 | US20010012837 Anti-ulcer composition |
| 08/09/2001 | US20010012836 Determining the presence or absence of a mutation in the nucleotide sequence or absence of a mutation in nucleotide sequence encoding the specific polypeptides in the genome of the subject and analyzing for presence of polypeptide |
| 08/09/2001 | DE10003493A1 Preparing complexes of cyclodextrin and coenzyme Q10, are useful for treating cardiac or degenerative diseases, by homogenizing starting materials with an input of energy |
| 08/09/2001 | CA2762121A1 The use of bicyclo [3.2.1]octan or kaurene for the treatment of non-insulin dependent diabetes mellitus, hypertension and metabolic syndrome |
| 08/09/2001 | CA2399982A1 G-protein coupled receptors |
| 08/09/2001 | CA2399792A1 Substituted amino acids as neutral sphingomyelinase inhibitors |
| 08/09/2001 | CA2399727A1 Narc-1, subtilase-like homologs |
| 08/09/2001 | CA2399686A1 Methods and materials relating to cub domain polypeptides and polynucleotides |
| 08/09/2001 | CA2399649A1 Methods and materials relating to leucine-rich repeat protein-like (lrr protein-like) polypeptides and polynucleotides |
| 08/09/2001 | CA2399083A1 Use of vitamin d-derivatives in the treatment of osteoporosis and related bone disorders, as well as novel vitamin d3-derivatives |
| 08/09/2001 | CA2399063A1 A method for maintaining or improving the synthesis of mucins |
| 08/09/2001 | CA2398996A1 Compounds having antitumor activity: process for their preparation and pharmaceutical compositions containing them |
| 08/09/2001 | CA2398995A1 Lipid hydrolysis therapy for atherosclerosis and related diseases |
| 08/09/2001 | CA2398754A1 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
| 08/09/2001 | CA2398674A1 Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same |
| 08/09/2001 | CA2398215A1 Methods and materials relating to preadipocyte factor-1-like (pref-1-like) polypeptides and polynucleotides |
| 08/09/2001 | CA2397076A1 Novel diphenylethylene compounds |
| 08/09/2001 | CA2369076A1 Pyrazole compositions useful as inhibitors of erk |
| 08/08/2001 | EP1122257A1 Benzimidazole compounds as ORL1-receptor agonists |
| 08/08/2001 | EP1122252A1 Nitrogenous fused heterocycle compounds, process for the preparation thereof and agents containing the same |
| 08/08/2001 | EP1121454A1 Extracellular novel rage binding protein (en-rage) and uses thereof |
| 08/08/2001 | EP1121449A1 Delivery system for porcine somatotropin |
| 08/08/2001 | EP1121444A2 Protein kinase homologs |
| 08/08/2001 | EP1121430A1 Human isre-binding protein |
| 08/08/2001 | EP1121419A1 Tnfr related gene 12 |
| 08/08/2001 | EP1121372A1 Adenine derivatives |
| 08/08/2001 | EP1121366A1 Prodrugs of phosphorous-containing pharmaceuticals |
| 08/08/2001 | EP1121155A2 Site-directed dual pegylation of proteins |
| 08/08/2001 | EP1121150A1 Delta 6 fatty acid desaturase |
| 08/08/2001 | EP1121145A1 Insulin preparations for pulmonary delivery containing menthol |
| 08/08/2001 | EP1121144A1 Stable concentrated insulin preparations for pulmonary delivery |
| 08/08/2001 | EP1121129A1 METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION |
| 08/08/2001 | EP1121125A1 Pharmaceutical formulations for use in estrogen deprivation syndrome |
| 08/08/2001 | EP1121121A2 Methods for inhibiting diabetic complications |
| 08/08/2001 | EP1121118A1 Formamides as therapeutic agents |
| 08/08/2001 | EP1121116A2 Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent |
| 08/08/2001 | EP1121115A1 Pufa supplements |
| 08/08/2001 | EP1121111A2 Compounds for the treatment of weight loss |
| 08/08/2001 | EP1054595A4 Methods and compounds for the genetic treatment of hyperlipidemia |
| 08/08/2001 | EP0824357B1 The use of epidermal growth factor as a gastrointestinal therapeutic agent |
| 08/08/2001 | EP0766682B1 Protein kinase c inhibitors |
| 08/08/2001 | EP0740679B1 Crosslinked polymeric ammonium salts |
| 08/08/2001 | CN1307561A Novel VLA-4 inhibitor: oMePUPA-V |
| 08/08/2001 | CN1307479A Neuroprotective composition for the prevention and/or treatment of nervous and behavioural alterations due to anxiety states or depression |
| 08/08/2001 | CN1307478A Food composition and method of using same |